MIRM
Mirum Pharmaceuticals, Inc.
$120.89
+1.85 (+1.55%)
At close · Jul 14
Market Cap
$7.32B
Shares
60,981,227
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$120.89
Open$119.72
Day$115.89–121.82
52W$50.25–130.00
Avg vol 30d914K
Short int7.5M · 12.3% float · 5.0d
Short vol72%
Last earningsMay 6, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.5 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+35%
above
Price vs 50-day avg
+13%
above
RSI (14)
58
neutral
MACD trend
Negative
52-week position
89%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+22%
trailing
6-month return
+32%
trailing
YTD return
+53%
this year
Relative strength
+21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $107 › 200d $90 — 50d above 200d
Institutional flow
Distributing
13 of 313 funds reported for Jun 30 · net -40.1K sh shares · +4 new
Insider flow
Distributing
Net -$4.0M over 90 days · 100% sells
Short interest
Rising
12.27% of float · ▲ +8.3% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
313 holders — near 3-yr high, broad support
Squeeze score
78
high risk · 0–100
Fundamentals
EPS growth
+75%
Y/Y
Free cash flow
$54.9M
Balance sheet
$296.7M
net cash
Quant / Vol
risk profile
Volatility
47%
annualized · 1-yr
Max drawdown
−21%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Net product sales
· full year 2026
Maintained
$660M – $680M
prior FY $521.31M
midpoint +28.5% Y/Y
Guided vs delivered
· last 1 settled
Revenues
full year 2025
$521.31M
Beat +3.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+35%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
58
Neutral
MACD trend
Negative
Bearish
52-week position
89%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $107 › 200d $90 — 50d above 200d
Institutional flow
Distributing
13 of 313 funds reported for Jun 30 · net -40.1K sh shares · +4 new
Insider flow
Distributing
Net -$4.0M over 90 days · 100% sells
Short interest
Rising
12.27% of float · ▲ +8.3% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
313 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $50
Now $121 · 89%
52-wk high $130
vs 200-day avg +35%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Bile Acid Medicines net product sales | $46.1M | first quarter 2026 | — |
| global net product sales | $159.9M | first quarter 2026 | — |
| LIVMARLI net product sales | $113.8M | first quarter 2026 | — |
| Anticipated liver healthcare professionals reached after expansion | 4,000 | Q1 FY2026 call | — |
| Estimated FOP patients globally | 900 | Q1 FY2026 call | — |
| Estimated FOP patients in the United States | 300 | Q1 FY2026 call | — |
| Planned U.S. field commercial personnel after expansion | 60 | Q1 FY2026 call | — |
| U.S. healthcare providers reached by liver field commercial team | 1,500 | Q1 FY2026 call | — |
| U.S. liver field commercial team size | 20 | Q1 FY2026 call | — |
| Countries with commercial access | 33 | full year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MIRM
this stock
Mirum Pharmaceuticals, Inc.
|
$7.32B | +53.0% | +54.7% | — | 12.3% |
|
ONC
BeOne Medicines Ltd.
|
$443.06B | +0.9% | +22179.2% | 901.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.09B | +5.1% | +46.2% | 28.3 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.66B | -14.9% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$53.96B | +2.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MIRM | -5.8% | +21.7% | +31.6% | +3.3% | +53.0% |
| SPY | +0.6% | +1.4% | +11.0% | +0.7% | +10.3% |
| vs SPY | -6.3% | +20.3% | +20.6% | +2.6% | +42.8% |
Key facts
CIK
1759425
CUSIP
604749101
13F (30d)
15 filings
14 filers
Visit website
Investor relations